News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Novartis to buy ophthalmology firm Encore Vision Swiss pharma buys treatment for common age-related vision problem.
News Novartis/Ophthotech eye combo fails in phase 3 Lucentis and pegpleranib combination misses goal in wet AMD.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
